The effect of gut glucagon-like immunoreactivity (GLI) devoid of pancreatic glucagon was studied in piglets. All glucagon-like peptides with an accessible C-terminal were removed from the gut extract by specific antibodies reacting with the C-terminal of the glucagon molecule. Endogenous secretion of pancreatic and gut glucagon was blocked by somatostatin infusion, and then the purified gut glucagon preparation was infused. The latter prevented the hypoglycemia resulting from somatostatin infusion, and increased the glucagon level detectable by C-terminal specific antibodies in the blood of the animals. This rise was significant statistically from the 30th min of GLI administration (26.7 ± 7.2 pg/ml versus 137.0 ± 67.0 pg/ml; P < 0.05) and increased until the end of the infusion (90th min, 218 ± 60 pg/ml; P < 0.005). It has been suggested that, owing to the in vivo enzymatic degradation of the infused gut glucagon, biologically active "pancreatic" glucagon fractions are formed extracellularly. DIABETES 30:792-794, September 1981. R ecently data have been accumulated pointing to the similarities of pancreatic glucagon derived from the A-cells of the pancreas and the stomach, and enteric glucagon-like immunoreactivity (GLI) produced by the L-cells of the gut, and raising the possibility of a common biosynthetic precursor. One of the components of gut GLI, the 100-amino acid polypeptide, glicentin, has been shown to contain the full sequence of glucagon, extended from the C-terminus by an additional 8-amino acid chain and from the N-terminus by a 63 amino-acid chain.
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Immunohistochemical studies have revealed glicentin not only in L-cells, but also in A-cells of the pancreas and the stomach. Moreover, the transformation of glicentin containing L-cells into cells showing immunoreactivity to antibodies against the C-terminal of the glucagon molecule, i.e., pancreatic glucagon (IRG), has been also successfully achieved by careful enzymatic treatment using trypsin and carboxypeptidase. 4 "Pulse-chase" study of the intact islets with labeled amino acids 6 and the translation studies with cell-free messenger RNA 3 provided further evidence to the theory of a common biosynthetic precursor. If glicentin is the precursor of glucagon synthesis and the difference between A-and L-cells is due to differential shortening of the product of the common primary gene, 1 -4 -7 then it would be reasonable to assume that: (1) enzymatic breakdown of the large molecular weight components of gut GLI should also proceed extracellularly and (2) when this process arrives at the level of pancreatic glucagon, i.e., at 3500 molecular weight, the biologic activity of pancreatic glucagon should become measurable.
In the present work, endogenous secretion of pancreatic and enteric glucagon was blocked by somatostatin infusion and the fate and activity of infused pancreatic glucagonfree GLI was studied in anesthetized piglets.
MATERIALS AND METHODS
Fresh porcine intestine was subjected to hydrochloric acidalcoholic extraction by the method of Kenny and Say. 9 The obtained extract was purified by double immunoaffinity chromatography using two different immunoadsorbents. One of the immunoadsorbents was prepared by binding the immunoglobulin fraction of the immune serum, which was attached to the N-terminal of the glucagon molecule, to Sepharose-4B (Pharmacia, Uppsala, Sweden) granules (Is-N), while the other was prepared from an immune serum specific against the C-terminal of the glucagon molecule (Is-Q) 10-12 p r j o r t 0 u s e these conjugates were washed with 6 M guanidinium hydrochloride and 0.1 M sodium bicarbonate buffer (pH 7.5) to remove all glucagon-like material bound to the antibodies. In the course of immunoaffinity chroma-tography the glucagon-like peptides were first isolated on the Is-N immunoadsorbent, from which they were eluted using 0.2 M glycine-HCI buffer (pH 2.4). The material thus obtained was further purified on the Is-C sorbent, which specifically bound the C-terminal of glucagon, collecting in this phase of the procedure the peptides running through the column, i.e., those not bound to antibodies. By this method, it was possible to remove from GLI all peptides which exhibited immunologic properties identical to that of the C-terminal of glucagon. The material thus obtained was stored after lyophilization.
Ten young piglets weighing 9.5-14.0 kg and anesthetized with fluothane were used in the experiments. Plastic cannulae were inserted into the external jugular veins. Afterwithdrawing two blood samples for basal hormone levels (-20 min and 0 min), the infusion of somatostatin (cyclic somatostatin, KabiVitrum, Stockholm, Sweden) was started at a rate of 1.11 /ug/min up to a total of 100 fxg. During the 90 min of infusion and on two occasions afterwards, blood samples were withdrawn every 10 min for glucose, insulin, IRG, and GLI determinations. The control animals (N = 5) were given only somatostatin while the experimental group (N = 5) received, 30 min after the start of the somatostatin infusion, gut glucagon (GLI) free of pancreatic glucagon at a constant rate of 15.2 ± 1.3 ng/kg/min, for 1 h.
Blood glucose was determined by the orthotoluidine method, plasma insulin, IRG, and GLI by radioimmunoassay. Glucagon and gut glucagon were assayed using antibodies specific to the C or N-terminal of the glucagon molecule. 10 GLI was estimated by subtracting from the amount of total glucagon established by the N-terminal antibody the concentration of IRG determined by the C-terminal antibody. Blood samples were collected in cooled tubes containing enzyme inhibitor and thrombostatic substances (aprotinin, Gordox, Gedeon Richter Ltd., Budapest, Hungary), 500 KIU; EDTA, 1.2 mg/ml, and spun at 4°C, then stored at -20°C until further use.
RESULTS
Insulin (IRI), IRG, GLI, and blood glucose levels in the control animals decreased promptly upon starting the somatostatin infusion (Figure 1 ), remaining at this low level throughout the infusion, and rose quickly after cessation of the infusion. In the experimental group, the decrease of blood glucose levels came to a halt after the start of GLI infusion, glucose concentration never reaching the hypoglycemic range as observed in the control animals. IRG level also increased, reaching statistical significance 30 min after the start of the infusion and attaining a statistically very highly significant elevation at the end of infusion (Figure 1 ).
DISCUSSION
Recent evidence suggests that biologic activity is linked with the N-terminal part of the glucagon molecule, while the C-terminal part probably only enhances binding of the hormone to the receptors. 15 This is also consistent with the observation that none of the larger molecule glucagons, i.e., pancreatic glucagon (IRG 14 Some earlier experimental data pointed to the biological activities arising as a consequence of degradation of the large molecule GLI fractions. It has been suggested on the basis of these observations that the large molecule GLI fraction exerts its lipolytic activity after having been transformed into smaller molecule GLI fraction in the adipose tissue. 5 As the gut contains not only GLI but IRG as well, 16 purification of GLI extracted from the intestine has to be based on a method that involves elimination from the extract all IRGtype peptides having already accessible C-terminals. In the present study, purified gut GLI was isolated by introducing the second (Is-C) affinity chromatography, thus the final preparation did not contain any free C-terminal glucagon fraction as detected by radioimmunoassay. Our aim has been only to separate the two families of peptides, i.e., to isolate GLI free of IRG without, however, separating the various GLI fractions of different molecular weight. The present results allow the assumption to be made that, following suppression of endogenous IRG and GLI secretion, the rise in
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TRANSFORMATION OF GLI OF GUT INTO PANGREATIC GLUCAGON IRG level that followed the infusion of exogenous GLI was due to the in vivo enzymatic breakdown of GLI molecules. The change in blood glucose that already preceded the rise in IRG might be accounted for, at least in part, by the GLI 4500 present in the GLI infusion, which is known to have some glycogenolytic activity.
The present results raise the possibility that the enzymatic breakdown of the common biosynthetic precursor of glucagon produced by the A-and L-cells of the gut and the pancreas, which starts intracellularly and proceeds in various directions, continues also extracellularly, resulting through a variety of fractions of different molecular weight in the formation of the biologically active glucagon molecule. The present in vivo data indicating physiologic transformation of gut glucagon into glucagon seem to provide an explanation as to why glucagon deficiency may not exist. The body has huge extrapancreatic GLI reserves from which, even after pancreatectomy, active glucagon may be formed through extracellular enzymatic processes.
